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We studied the incidence of reported tularaemia by 
year and region and the prevalence of antibodies 
against Francisella tularensis in the adult general 
population in Finland. Moreover, we assessed the cor-
relation between vole population cycles and human 
tularaemia outbreaks. The seroprevalence study made 
use of serum samples from a nationwide population-
based health survey (Health 2000). The samples of 
1,045 randomly selected persons, representative for 
the Finnish population in each region, were screened 
with an enzyme-linked immunosorbent assay (ELISA) 
for the presence of IgG antibodies against F. tularen-
sis, and positive results were further confirmed by 
immunoblotting. A serological response to F. tularen-
sis was found in 2% (95% confidence interval: 1.1–3.5) 
of the population. Incidence and seroprevalence were 
highest in the same areas, and vole population peaks 
clearly preceded tularaemia outbreaks one year later. 
Introduction
Tularaemia is a zoonotic disease caused by the intra-
cellular bacterium Francisella tularensis [1,2]. The dis-
ease is caused primarily by two of four subspecies: the 
highly virulent type A strain F. tularensis subsp. tula-
rensis which is almost completely restricted to North 
America, and the less virulent type B strain F. tularen-
sis subsp. holarctica, which occurs in many regions of 
the northern hemisphere, including Finland [1,2].
Recurrent outbreaks with hundreds of cases are 
reported in Finland and Sweden [3,4]; in other European 
countries, the disease is rare, but many countries report 
sporadic outbreaks [5-7]. Geographically, the disease 
shows a focal distribution [8]. The pathogen is most 
likely to persist in the local environment but seems 
to cause epidemics only when the ecological condi-
tions are favourable for an active infectious cycle [9]. 
Thus, appropriate reservoirs, amplifiers, vectors and 
suitable climatic conditions are needed for an outbreak 
of human tularaemia [9]. Tularaemia is typically associ-
ated with outdoor activities, and farmers and hunters 
are at particular risk for infection [3-7,10]. In Finland 
and Sweden, the disease is typically mosquito-trans-
mitted and most cases are reported during August and 
September in connection with the occurrence of late 
summer mosquito species [3,4], whereas in Norway, 
the disease occurs in autumn and winter and the most 
common source is drinking water contaminated by 
rodents [11]. Outbreaks in Norway and Kosovo* have 
been linked to high rodent densities [11-14].
Airborne outbreaks, mainly associated with activities 
that can generate aerosols, such as farming, gardening 
or hunting, occur occasionally in all endemic countries 
and are very local [5-7,15].
Human tularaemia typically starts with non-specific 
influenza-like symptoms [16]. Other clinical manifes-
tations depend mainly on the route of transmission, 
and the disease severity depends on the infecting sub-
species and strain [1,16]. After infection, antibodies 
against F. tularensis rise slowly but are detectable for 
several years [17]. Here we report a study conducted in 
Finland, aiming to determine the incidence of tularae-
mia and the prevalence of F. tularensis antibodies in 
the population in 2000 and 2001, to compare the sero-
prevalence rates with the number of reported cases for 
the period 1995 to 2013, and to assess for the same 
period the role of vole population cycles in the tempo-
ral and spatial pattern of human tularaemia outbreaks.
Methods
National laboratory-based surveillance
The Finnish national healthcare system is organised 
in 20 geographically and administratively distinct 
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healthcare districts. Laboratory-confirmed tularaemia 
has been a notifiable disease by the diagnosing labora-
tory since 1995, and clinical microbiology laboratories 
report cases directly to the National Infectious Disease 
Register (NIDR) which is maintained by the National 
Institute for Health and Welfare (THL). Diagnostic cri-
teria for reporting include (i) isolation of F. tularensis 
in a clinical specimen, (ii) a more than four-fold rise in 
serum antibody titre or a single antibody titre of > 160 
when using an agglutination assay or (iii) the presence 
of specific IgM and IgG antibodies in the serum when 
an enzyme-linked immunosorbent assay (ELISA) is 
used. With each notification, the following information 
is given: date and type of specimen, date of birth, sex, 
place of treatment and place of residence.
Human serum samples and background health 
information
Serum samples were collected in a multidisciplinary 
epidemiological health survey, the Health 2000 Study, 
carried out in the years 2000–01 in Finland [18]. 
Detailed study methods have been described else-
where [18]. Sera from adults were collected in 80 differ-
ent areas covering most of the country. For the current 
study, serum samples from 1,045 randomly selected 
persons were included. For geographical coverage, 
all 20 healthcare districts were represented with 50 
samples, except for Central Ostrobothnia where only 
45 samples were available and the capital district of 
Helsinki and Uusimaa, which was represented with 
100 samples, reflecting a union of two formerly sepa-
rate districts. An extensive health interview and health 
examination had been done for all participants in the 
original study. In this study, we especially focused our 
analyses on common symptoms and medical condi-
tions, living environment, occupation, leisure activi-
ties, physical condition, smoking and alcohol use and 
demographic factors. The Health 2000 Survey was 
approved by the Ethical Committee for Research in 
Epidemiology and Public Health at the Hospital District 
of Helsinki and Uusimaa.
Sera from seven patients who had laboratory-con-
firmed tularaemia (diagnosed at the Department of 
Medical Microbiology and Immunology, University of 
Turku) one to 16 years before serum collection, were 
used as positive control sera.
Serological testing
ELISA
All serum samples were screened for F. tularensis anti-
bodies by ELISA as previously described [17], with whole 
bacterium lysate prepared from F. tularensis live vac-
cine strain (LVS) as the antigen. Serum samples were 
tested at a dilution of 1:100. Absorbances (OD405) were 
measured with BEP III apparatus (Siemens Healthcare 
Diagnostics Products GmbH, Erlangen, Germany). 
Results were expressed as arbitrary enzyme-immuno-
sorbent units (EIU) on the scale from zero to 100 units. 
Conventional receiver operating characteristic ROC) 
analysis to determine the cut-off of the ELISA could not 
be performed because the true tularaemia antibody 
status (defined by a gold standard) of our samples or 
for the ELISA test in general was not known. This is why 
a confirmatory Western blot was employed.
Western blot
Western blotting was conducted as earlier described 
[19]. Positive sera showed a typical lipopolysaccharide 
(LPS) band pattern at a dilution of 1:100. Samples were 
screened from the highest EIU (83.7) in ELISA down to 
EIU 26.8 (including 55 serosurvey samples and seven 
positive control samples). The lowest ELISA EIU value 
that was still positive in Western Blot was 28.5. The 
following 10 samples were WB negative and screen-
ing was stopped due to low EIU values of the remain-
ing samples. Only samples positive in both EIA and WB 
were considered positive.
Vole data
Data on small mammals were collected biannually 
in ca 30 locations around the country by the Natural 
Resources Institute, as described by previously [20]. 
The trapped mammals were predominantly voles, 
which dominate the rodent and other small mammal 
fauna in Finland [20,21]. Only vole populations show 
cyclic fluctuations. In addition, three wild murine (i.e. 
non-vole rodent) species inhabit Finland, but they are 
restricted to the southern half of the country, and usu-
ally occur at low densities with seasonal, but not cyclic 
dynamics. As such, the national monitoring programme 
of vole populations was planned to produce compre-
hensive data on the spatiotemporal dynamics of vole 
population fluctuations around the whole country. By 
and large, vole populations in Finland fluctuate pro-
nouncedly in cycles of three to four years [20]. For the 
purposes of this study, the vole population data (den-
sity indices; voles per 100 trap nights) were qualita-
tively classified into three distinct cyclic phases, each 
corresponding to a year: population peak years, popu-
lation decline years and population increase years.
Statistical analyses
Serological survey
Statistical analyses were performed using IBM SPSS 
Statistics version 22 and the programme R maptools 
package was used to construct the maps. Our dataset 
was a subsample selected from the Health 2000 sur-
vey main study by stratified simple sampling of size 50 
samples per hospital district, and the original sampling 
weights were reweighted to match the population size 
of a given hospital district at year 2000. Of the very 
comprehensive background information, we especially 
focused our analyses on common symptoms and medi-
cal conditions, living environment, occupation, leisure 
activities, physical condition, smoking and alcohol 
use and demographic factors. Univariate chi-square 
tests were computed taking into account the sam-
pling design, its strata and clusters and the sampling 
weights for the test of independence of the categorical 
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variables. The population sizes and prevalences were 
estimated accordingly, taking into account sampling 
design. Logistic regression was used to model the rela-
tionship between seroprevalence odds and explanatory 
variables. The incidence ratio of notified/total tularae-
mia cases was calculated assuming that the popula-
tion at risk and the prevalence pool were stationary. 
Applying a formula for a time stationary situation, the 
(sero)prevalence odds of tularaemia p / (1 − p) , the 
mean total incidence I and the mean duration of the 
seroprevalence D are related as p / (1 − p) = I × D, with 
D equal to the estimated average residual life time 
after the mean age of acquiring tularaemia. 
Vole and surveillance data analysis
The association between tularaemia outbreaks and 
phase of vole cycle was analysed with Poisson regres-
sion. Poisson model calculations were done by hospi-
tal district. The effect of vole cyclic phase factor was 
assumed independent of the year. Possible overdis-
persion was corrected by Pearson chi-squared scale 
parameter method, and possible autocorrelations 
of person residuals from the model were checked by 
autocorrelation plots (ACF plots).
Results
National laboratory-based surveillance
From 1995 to 2013, 5,086 notifications of laboratory-
confirmed tularaemia cases were reported to the NIDR. 
The annual number of notified cases ranged from 14 
to 926. The average annual incidence was 5.1/100,000 
population and the highest incidence (18/100,000 pop-
ulation) was recorded during the year of the major epi-
demic in 2000 (Figure 1). 
Rates were typically highest in the health districts 
of Northern and Southern Ostrobothnia and Central 
Finland. The mean age of the cases was 45 years 
(range: 0–93 years) and 55% were male. The annual 
variation in reported cases in the three healthcare 
districts with particularly high incidence is shown in 
Figure 2. Typically, epidemics occurred in different dis-
tricts every third or fourth year.
 
Epidemics were strongly seasonal, with the majority 
of cases diagnosed during summer and early autumn 
(Figure 3). 
Figure 4 shows the incidence rates by healthcare dis-
trict in 1995–2000, five to six years before sampling for 
the seroprevalence study.
Human seroprevalence study
Our study sampling of 1,045 persons comprised 46% 
men and 54% women. Their mean age was 53 years 
(range: 30–92 years) and for geographical coverage, 
they represented all 20 healthcare districts. We found 
16 positive samples (1.5%), which after adjustment with 
survey weights gave an estimated overall F. tularensis 
antibody prevalence of 2.0% (95% confidence interval: 
1.1–3.5) on population level. The distribution of EIU val-
ues in our study and control samples is shown in Figure 
5; the positive control sera showed EIU values between 
64.3 and 93.0. 
Five participants had an EIU value > 50 in addition to 
a typical LPS band pattern in the Western Blot (Figure 
6). One of them reported being hospitalised because of 
tularaemia during the period from 1995 to 2000 (pre-
cise time and duration of hospitalisation not available).
Figure 1
Incidence rates of laboratory-confirmed tularaemia infections, Finland, 1995–2013
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Figure 2
Number of laboratory-confirmed tularaemia cases and timing of vole population peaks, by district, Finland, 1995–2013 
((n = 3,011)
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Geographically, the seroprevalence was highest in 
Northern Ostrobothnia (Figure 7). 
No significant differences in age or sex distribution 
were found between the seropositive and seronega-
tive group. The mean age of seropositive persons in 
our study was 55 years and 50% of them were males. 
No single risk factor was significantly associated with 
seropositivity. F. tularensis seropositivity in general 
was higher in persons with lower educational level 
(likelihood ratio: 0.048), but no single occupation was 
related to seropositivity. The ratio of notified vs total 
(estimated based on the observed seroprevalence) F. 
tularensis infections was 1/10.5.
Vole cycles and their association with human 
tularaemia
The temporal occurrence of vole peak years clearly pre-
dicted human tularaemia outbreaks. Outbreaks mostly 
occurred during the years immediately after the vole 
peak years, i.e. in decline years (Figure 2). The tularae-
mia incidence in vole decline years was on average ca 
six times higher than in rodent increase years (Table). 
In 10 of the 20 hospital districts, the vole decline years 
had a significantly higher tularaemia incidence (inci-
dence rate ratio > 1) than the non-decline years. In the 
remaining districts, tularaemia is rare and the impact 
of vole cycles could not be observed (the regression 
model could not be fitted to those particular hospital 
districts).
Discussion
The epidemiology of tularaemia in Finland is charac-
terised by recurrent regional and seasonal outbreaks 
occurring in short cycles of typically three to four 
years [3,21]. In the long term, the incidence is high-
est in Northern Ostrobothnia as shown also in the 
current study. Outbreaks involving hundreds of cases 
occur every three to five years in some areas such 
as Northern and Southern Ostrobothnia and Central 
Finland [3]. In other areas, outbreaks of this magni-
tude are rare. The majority of cases are reported in 
August and September, during or right after the late 
summer mosquito season. It has been shown that the 
F. tularensis carriage rate in mosquitoes in Sweden 
increases with declining mosquito populations in late 
summer and early autumn [22], which may explain the 
high number of notifications in August and September. 
Also other important mosquito-transmitted diseases in 
Finland (such as Pogosta disease caused by Sindbis 
virus) are transmitted particularly by the late summer 
mosquito species [23].
On the other hand, there is generally a time lag of sev-
eral weeks between onset of symptoms and labora-
tory confirmation of tularaemia [3]. Presumably, most 
cases notified in August and September acquired the 
infection some weeks earlier. In our serological sur-
vey, we found an overall F. tularensis antibody preva-
lence of 2% on population level after adjustment with 
survey weights (1.5% among our study participants). 
Seroprevalence was highest in Northern Ostrobothnia, 
which is in line with the number of notifications to the 
NIDR. The observed seroprevalence was comparable 
to results from Germany where seroprevalences up to 
2.3% have been found [24,25]. In Martha’s Vineyard, 
Massachusetts, where only landscapers were tested, 
9.1% of the studied population was seropositive for 
F. tularensis [10]. In rural Azerbaijan [26] and Iran [27], 
seroprevalences significantly higher than in our study 
were found. In those studies, rodent exposure [26] and 
hunting [27] were shown to clearly increase the risk 
of tularaemia. These are well known risk factors for 
tularaemia.
It was surprising that the F. tularensis antibody prev-
alence was so low in Finland the European Union 
Member State with the highest reported tularaemia 
incidence [21,24]. On the other hand, low incidence 
but relatively high seroprevalence in other countries 
probably indicates underdiagnosing. This could be 
explained by the different clinical picture: in Finland, 
tularaemia is mainly mosquito-borne and manifests 
as the ulceroglandular form which is easy to diagnose 
based on the typical symptoms. In central and south-
ern Europe however, the most common is the typhoidal 
form which is very difficult to diagnose because simi-
lar symptoms can have other causes and because the 
awareness among clinicians is low. Also in Finland, a 
certain proportion of infections are not notified, which 
is not surprising, especially when taking into account 
the challenging laboratory diagnosis of tularaemia. 
General practitioners in endemic areas probably often 
treat the disease based on a clinical diagnosis only and 
diagnostic laboratory tests are not requested. Some 
patients may also recover after an influenza-like febrile 
illness without seeking medical attention [10]. On the 
other hand, the low prevalence of antibodies against 
F. tularensis indicates that tularaemia infection is not 
very common and is in most cases associated with 
distinct acute clinical symptoms [2,16]. Based on the 
Figure 3
Cumulative number of laboratory-confirmed tularaemia 
cases by month, Finland, 1995–2013 (n = 5,086 )
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notifications and serocoprevalence, we estimate that 
ca one in 10 (9.5%) F. tularensis infections are notified.
We have shown a correlation between vole population 
dynamics and human tularaemia outbreaks. Human 
tularaemia outbreaks typically occur during the vole 
decline phase a year after the vole population peak. In 
2000, human tularaemia outbreaks occurred through-
out Finland, including Southern Ostrobothnia and 
Central Finland, although characteristics of a wide-
spread vole peak in the preceding year were only met in 
the northern part of the country. Vole peaks occurred in 
a patchy fashion in 1999, and particularly in Southern 
Ostrobothnia, our long-term monitoring sites repre-
senting the large hospital districts may not have coin-
cided with the localised vole peak areas [28]. We did 
not include 1999 as a peak year in our statistics, but 
Figure 4
Incidence of laboratory-confirmed Francisella tularensis infections reported to the National Infectious Disease Register, by 
healthcare district, Finland 1995–2000
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the association between the cyclic phase and human 
tularaemia was nevertheless significant.
We have previously shown that voles can serve as 
amplification hosts for F. tularensis [29]. Large vole 
populations allow the bacteria to replicate intensively. 
During a peak phase, live rodents can shed the bac-
teria into the environment, and in the decline phase, 
infected dead rodents release large amounts of F. tula-
rensis into the environment, including breeding sites 
of mosquitoes [29]. Mosquito larvae can take up the 
bacteria [22] and once they become adults, spread the 
bacteria to susceptible hosts that act as local ampli-
fiers. This provides a likely explanation for the sug-
gested association between vole cycles and human 
tularaemia incidence [29]. However, the variation in the 
magnitude and the locality of human tularaemia out-
breaks warrant further analyses. High vole density is 
probably one, but not the only prerequisite for tularae-
mia outbreaks. The local ecological factors crucial for 
disease outbreaks are still not known very well. It has 
been shown that the presence of certain aquatic amoe-
bae enhances the multiplication of F. tularensis and 
that its infection process in amoebae resembles that 
in macrophages [30]. Possibly vole carcasses contami-
nate natural waters, amoebae support the local persis-
tence of F. tularensis in these waters, mosquito larvae 
feed on these protozoa and thus get infected. Weather 
conditions influence the amount of mosquitoes, which 
impacts on the transmission to humans and thus the 
amplitude of the outbreak [31].
Conclusion
In summary, human tularaemia in Finland is focal, and 
most of the cases occur in a few districts. This warrants 
landscape ecological analyses [8,32]. The answer may 
not be simple because the endemic provinces differ 
considerably in topography. The seasonality of tularae-
mia occurrence strongly indicates a major role of 
mosquitoes in disease spread. The multiannual cyclic 
pattern of the epidemics is associated with vole den-
sity cycles, with vole peak years preceding epidemic 
years. The interactions between voles, mosquitoes and 
F. tularensis need still further studies, as well as the 
discrepancy between the relatively low seroprevalence 
and considerable incidence of tularaemia. 
Figure 5
Distribution of ELISA results, tularaemia seroprevalence 
study, Finland, 2000–01 (n = 1,045) 
ELISA: enzyme-linked immunosorbent assay; EIU:  
enzyme-immunosorbent units.
Blue bars: study samples; green bars: positive control samples.
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Figure 6
Western blot of representative positive and negative sera, 
tularaemia seroprevalence study, Finland, 2000–01
Lanes 1, 2 and 5: samples considered Fransicella tularensis 
antibody-positive according to a typical ladder pattern; lanes 
3 and 4: negative samples from the serosurvey panel; lane 6: a 
sample considered as an unspecific reaction. M: size marker.
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Table
Incidence of tularaemia in different hospital districts and its relation to rodent cycles, Finland, 1995–2013 
Hospital district Vole cycle phase Cases (n) Population Incidence IRR 95% Wald CI for IRR p value
Southern Karelia
non decline years 6 1,417,302 0.42 3.14 0.98 10.01 0.05
decline years 12 902,885 1.33
Southern Ostrobothnia
non decline years 111 2,164,737 5.13 7.37 2.83 19.22 < 0.001
decline years 522 1,381,053 37.80
Southern Savo
non decline years 15 1,149,203 1.31 1.46 0.47 4.53 0.51
decline years 14 732,287 1.91
Helsinki and Uusimaa
non decline years 100 15,789,947 0.63 4.29 2.15 8.55 < 0.001
decline years 272 10,020,284 2.71
Eastern Savo
non decline years 2 702,300 0.28 18.08 0.61 536.11 0.09
decline years 23 446,602 5.15
Kainuu
non decline years 3 1,245,547 0.24 3.28 0.63 17.01 0.16
decline years 2 253,206 0.79
Kanta-Häme
non decline years 9 1,856,789 0.48 5.07 1.90 13.49 < 0.001
decline years 29 1,181,058 2.46
Central Ostrobothnia
non decline years 204 931,902 21.89 1.22 0.16 9.36 0.85
decline years 124 462,955 26.78
Central Finland
non decline years 233 2,934,836 7.94 4.89 1.95 12.26 < 0.001
decline years 725 1,865,762 38.86
Kymenlaakso
non decline years 78 1,991,154 3.92 2.58 0.86 7.69 0.09
decline years 128 1,267,302 10.10
Lapland
non decline years 15 2,074,033 0.72 2.34 0.41 13.32 0.34
decline years 2 118,189 1.69
Western Ostrobothnia
non decline years 20 1,149,854 1.74 0.00 0.00 0.00 < 0.001
decline years 0 64,655 0.00
Päijänne Tavastia
non decline years 17 2,293,263 0.74 2.03 0.48 8.63 0.34
decline years 22 1,459,719 1.51
Pirkanmaa
non decline years 104 5,098,236 2.04 3.60 0.88 14.84 0.08
decline years 238 3,237,195 7.35
Northern Karelia
non decline years 11 1,885,503 0.58 0.71 0.19 2.70 0.62
decline years 5 1,203,895 0.42
Northern Ostrobothnia
non decline years 408 4,931,836 8.27 6.75 3.31 13.75 < 0.001
decline years 1,060 1,898,901 55.82
Northern Savo
non decline years 20 2,764,993 0.72 4.95 2.04 12.00 < 0.001
decline years 63 1,760,755 3.58
Satakunta
non decline years 54 2,519,350 2.14 10.77 2.75 42.20 < 0.001
decline years 371 1,607,604 23.08
Vaasa
non decline years 29 1,996,883 1.45 7.58 2.74 20.99 < 0.001
decline years 110 999,243 11.01
South-west Finland
non decline years 11 5,038,620 0.22 6.87 2.63 17.95 < 0.001
decline years 48 3,201,242 1.50
Whole country
non decline years 1,450 59,936,288 2.42 4.57 4.31 4.86 < 0.001
decline years 3,770 34,064,792 11.07
CI: confidence interval; IRR: incidence rate ratio.
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Figure 7
Estimated seroprevalence (prevalence of Western blot positive samples), by healthcare district, tularaemia seroprevalence 
study, Finland, 2000–01 (n = 1,045)
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